Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | IGC Pharma, Inc.: IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs | 182 | ACCESS Newswire | Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen | |
08.04. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program | 250 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with... ► Artikel lesen | |
01.04. | IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health | 232 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation... ► Artikel lesen | |
26.03. | IGC Pharma, Inc.: IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances | 337 | ACCESS Newswire | - IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company")... ► Artikel lesen | |
20.03. | IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences | 216 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the... ► Artikel lesen | |
17.03. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida | 229 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's... ► Artikel lesen | |
12.03. | IGC Pharma, Inc.: IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" | 164 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report... ► Artikel lesen | |
IGC PHARMA Aktie jetzt für 0€ handeln | |||||
10.03. | IGC Pharma, Inc.: IGC Pharma Announces Equity Analyst Update by Alliance Global Partners about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" | 199 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update... ► Artikel lesen | |
06.03. | IGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer's Diagnosis | 1 | Insider Monkey | ||
04.03. | IGC Pharma, Inc.: IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection | 230 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development... ► Artikel lesen | |
20.02. | IGC Pharma, Inc.: IGC Pharma Expands Holiby Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market | 120 | ACCESS Newswire | - New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen | |
18.02. | IGC Pharma GAAP EPS of -$0.02, revenue of $257M | 1 | Seeking Alpha | ||
18.02. | IGC Pharma, Inc.: IGC Pharma Reports Third Quarter Fiscal 2025 Results | 292 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended... ► Artikel lesen | |
11.02. | IGC Pharma, Inc.: IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby | 261 | ACCESS Newswire | - Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc.... ► Artikel lesen | |
28.01. | IGC Pharma, Inc.: IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease | 308 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE... ► Artikel lesen | |
21.01. | IGC Pharma, Inc.: IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor | 477 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of... ► Artikel lesen | |
13.01. | IGC Pharma, Inc.: IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets | 279 | ACCESS Newswire | POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside... ► Artikel lesen | |
08.01. | IGC Pharma, Inc.: IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy | 319 | ACCESS Newswire | Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced... ► Artikel lesen | |
20.12.24 | IGC Pharma, Inc.: IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 | 584 | ACCESS Newswire | POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM... ► Artikel lesen | |
02.12.24 | IGC Pharma, Inc.: IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology | 330 | ACCESS Newswire | New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's diseaseExpanded research positions IGC-AD1 as a potential treatment targeting the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 21,030 | 0,00 % | Bayer, BioNtech, Defence Therapeutics: Die neue Biotech-Realität eröffnet Chancen | Die Pharmabranche ist von den US-Zöllen ausgenommen. Doch wird für die Branche damit alles gut? Während der German Biotech Days in Heidelberg, die in der vergangenen Woche stattfanden, zeigten sich... ► Artikel lesen | |
NOVO NORDISK | 51,88 | 0,00 % | Nur SAP, Novo Nordisk wertvoller: Hermès überholt LVMH - Luxus-Purist wird teuerstes Unternehmen Frankreichs | Unbeachtet von den meisten hat sich der Luxuskonzern Hermès zum Unternehmen mit der dritthöchsten Bewertung in Europa gemausert. Sehr zum Ärger des "Wolfs in Kaschmir".Der Luxuskonzern Hermès hat Geschichte... ► Artikel lesen | |
PFIZER | 19,478 | +0,02 % | Übernahmespekulationen! Das ist los bei Pfizer, Sanofi, NetraMark | Medikamente entwickeln ist teuer. So teuer, dass 22 % aller Phase-III-Studien am Budget scheitern. Das zeigen wissenschaftliche Untersuchungen. Wenn Pharmaunternehmen ein Projekt in der Spätphase einstellen... ► Artikel lesen | |
NOVARTIS | 96,90 | -100,00 % | Novartis: Das Allzeithoch ist in Schlagdistanz! | ||
MERCK KGAA | 116,65 | 0,00 % | GOLDMAN SACHS stuft MERCK KGAA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Merck KGaA von 177 auf 169 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Die Zoll-Belastungen dürften die... ► Artikel lesen | |
GILEAD SCIENCES | 91,99 | +0,08 % | Gilead Sciences Reports Positive Data From Phase 3 ASCENT-04/KEYNOTE-D19 Study | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) Monday reported positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating Trodelvy in combination with Merck's Keytruda... ► Artikel lesen | |
AURORA CANNABIS | 3,860 | -1,28 % | Aurora Cannabis Inc (3): Aurora Cannabis offers inhalers to U.K. patients | ||
SANOFI | 90,51 | 0,00 % | Sanofi's Dupixent gets FDA nod for chronic hives indication | ||
ABBVIE | 152,20 | 0,00 % | Dividendenbekanntmachungen (15.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-MARK PRECIOUS METALS INC US00181T1079 0,2 USD 0,1761 EUR ABBOTT LABORATORIES US0028241000 0,59 USD 0,5195 EUR ABBOTT LABORATORIES US0028241000 0... ► Artikel lesen | |
CANOPY GROWTH | 1,052 | +0,77 % | It's Been Six Years Since Canopy Growth Made This Industry-Rocking Announcement | ||
ELI LILLY | 739,30 | 0,00 % | Eli Lilly-Aktie explodiert plötzlich zweistellig: Und was macht Konkurrent Novo Nordisk? | Eine neue klinische Studie zu einer Abnehmpille lässt die Aktien von Eli Lilly in die Höhe schießen. Welche Auswirkungen hat das auf die Papiere des größten Konkurrenten Novo Nordisk? Nach den ganzen... ► Artikel lesen | |
MERCK & CO | 68,60 | 0,00 % | Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer | ||
ASTRAZENECA | 118,75 | 0,00 % | Astrazeneca Aktie: Details zum strategischen Plan | Trotz aktueller Schwächephase halten Analysten an Kaufempfehlungen fest - Dividendenankündigung und Quartalszahlen im Fokus. Die AstraZeneca-Aktie zeigt sich diese Woche widersprüchlich: Während Aktionäre... ► Artikel lesen | |
TILRAY BRANDS | 0,400 | +0,78 % | Tilray Brands, Inc.: Tilray Brands Announces Proposed Reverse Stock Split and Corresponding Special Meeting of Stockholders | NEW YORK and LEAMINGTON, Ontario, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at... ► Artikel lesen | |
BRISTOL-MYERS SQUIBB | 43,665 | +0,88 % | Bristol Myers Squibb: Bittere Pille | Der US-amerikanische Pharma-Konzern Bristol Myers Squibb muss einen herben Studienrückschlag verkraften. Die Substanz Mavacamten, die sich das Unternehmen durch die milliardenschwere Übernahme von MyoKardia... ► Artikel lesen |